Cryostem and Biosolutions are conducting a first-of-its-kind cellular therapy clinical study as part of the protocol entitled: ATCell™ Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells Deployed via Intravenous Infusion for the Treatment of Post Concussion Syndrome (PCS) in Retired Military and Athletes. This study is being conducted during Cyrostem’s IND filing with the FDA.
Biosolutions is located in Mesa, CA, and seems to be a good fit for Cryostem’s agenda. BioSolutions’s expertise and previous experiences with cellular therapy trials and local clinical sites provide sponsors with consistent subject enrollment and accurate data. BioSolutions conducts clinical trials in both Industrial Sponsored Research (ISR) and Stem Cell Research (SCR). And with over 25 years of collective experience in the many fields of medicine, Biosolutions employs community-based investigators and researchers all working together as they oversee all aspects of the clinical trials. They produce quality research data while recognizing that speed, responsiveness and accountability are also core needs.
Anthony Dudzinski, COO of CryoStem, stated: “This is a first of its kind cellular therapy clinical study utilizing adipose derived cultured mesenchymal stem cells that initially seeks to confirm the safety of individual infusion therapy to address the significant inflammatory response to concussive injury.”
Call to Action: Are you or someone you know in the military or field of athletics? We invite you to use TrialSite’s courtesy concierge services to get in touch with study investigators. You can also learn more about the merger of these two companies here.